Kinetics of Plasma and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Patients With Ischemic Stroke
BDNF
1 other identifier
interventional
50
1 country
1
Brief Summary
The aim of this study is to show for the first time that treatment with intravenous fibrinolysis using rt-PA in patients with recent ischemic stroke is accompanied by increases in circulating levels of BDNF, which may reflect an increase in BDNF synthesis in the brain. The analysis of the recovery of functional and cognitive abilities as well as mood at 3 months will allow us to study the impact of BDNF on these parameters. Thus, depending on the results obtained, circulating BDNF could serve as an early marker of these.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2012
CompletedFirst Submitted
Initial submission to the registry
August 1, 2016
CompletedFirst Posted
Study publicly available on registry
August 9, 2016
CompletedMarch 12, 2026
March 1, 2026
11 months
August 1, 2016
March 10, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Measurement of plasma levels of BDNF
Change from baseline at Day1, Day 7 and Month 3
Measurement of serum levels of BDNF
Change from baseline at Day1, Day 7 and Month 3
Study Arms (2)
Patients with fibrinolysis
EXPERIMENTALPatients without fibrinolysis
PLACEBO COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- Patients (or their person of trust in cases of inability) who have been informed about the research and given their consent to take part
- Patients aged 18 years or older
- Patients who have suffered a de novo recent ischemic stroke \< 12 hours
- Patients who had cerebral imaging (CT-Scan or MRI)
- Ischemic stroke severity, measured by the National Institute of Health Stroke Score (NIHSS), between 4 and 20
You may not qualify if:
- Patients without national health insurance cover
- Patients with a clinical history of stroke
- Patients with cerebral or sub-arachnoid haemorrhage
- Patients with a transient ischemic attack
- Time of symptom onset unknown
- Patients with severe aphasia at the time of the ischemic stroke defined by a sub-score for item 9 (best language) of the NIHSS ≥ 2
- Patients with dementia prior to the ischemic stroke
- Patients with a significant loss of autonomy prior to the ischemic stroke, defined by a Rankin score ≥ 4
- Patients with aphasia before the ischemic stroke
- Patients with a contra-indication for cerebral MRI
- Pregnant or breast-feeding women
- Adults under guardianship
- Subjects in custody
- Patients who do not speak French
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Centre Hospitalier Universitaire
Dijon, 21079, France
Related Publications (1)
Rodier M, Quirie A, Prigent-Tessier A, Bejot Y, Jacquin A, Mossiat C, Marie C, Garnier P. Relevance of Post-Stroke Circulating BDNF Levels as a Prognostic Biomarker of Stroke Outcome. Impact of rt-PA Treatment. PLoS One. 2015 Oct 15;10(10):e0140668. doi: 10.1371/journal.pone.0140668. eCollection 2015.
PMID: 26469350RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 1, 2016
First Posted
August 9, 2016
Study Start
February 1, 2011
Primary Completion
January 1, 2012
Last Updated
March 12, 2026
Record last verified: 2026-03